TriangleFOR PATIENTS · SOURCE READING
Treatment of Transient Abnormal Myelopoiesis or Children with Down Syndrome and AML
Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 5, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Transient abnormal myelopoiesis (TAM) usually goes away on its own. For newly diagnosed TAM that does not go away on its own or causes other health problems, treatment may include the following:
Source links and citations
Supportive care, including transfusion therapy or leukapheresis.
Source links and citations
Chemotherapy.
Source links and citations
Treatment of newly diagnosed acute myeloid leukemia (AML) in children aged 4 years or younger who have Down syndrome may include the following:
Source links and citations
Combination chemotherapy plus central nervous system prophylaxis therapy with intrathecal chemotherapy.
Source links and citations
A clinical trial of a new chemotherapy regimen that depends on how the child responds to initial chemotherapy.
Source links and citations
Treatment of newly diagnosed AML in children older than 4 years who have Down syndrome may be the same as treatment for children without Down syndrome.
Preserved source evidence · Independent clinical review pending · Not medical advice